General Information of Drug (ID: DM4GO8H)

Drug Name
Guanidine
Synonyms
(NH2)2C=NH; 4-03-00-00148 (Beilstein Handbook Reference); AC1L1G4E; AC1Q50DT; AC1Q50DU; Aminoformamidine; Aminomethanamidine; Carbamamidine; Carbamidine; GAI; Gu; Guanidin; Guanidine, Hydrochloride; Guanidine, free base;BRN 0506044; H2N-C(=NH)-NH2; HSDB 7603; Imidourea; Iminourea; JU58VJ6Y3B; NCIOpen2_007946; UNII-JU58VJ6Y3B; ZRALSGWEFCBTJO-UHFFFAOYSA-N; guanidine
Indication
Disease Entry ICD 11 Status REF
LambertEaton myasthenic syndrome 8C62 Approved [1]
Affected Organisms
Humans and other mammals
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski):
0
Molecular Weight 59.072
Logarithm of the Partition Coefficient Not Available
Rotatable Bond Count 0
Hydrogen Bond Donor Count 3
Hydrogen Bond Acceptor Count 1
ADMET Property
Absorption
The drug is rapidly absorbed and distributed []
Half-life
The concentration or amount of drug in body reduced by one-half in 7 - 8 hours [2]
Metabolism
The drug is not metabolised []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 592.50598 micromolar/kg/day [3]
Chemical Identifiers
Formula
CH5N3
IUPAC Name
guanidine
Canonical SMILES
C(=N)(N)N
InChI
InChI=1S/CH5N3/c2-1(3)4/h(H5,2,3,4)
InChIKey
ZRALSGWEFCBTJO-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3520
ChEBI ID
CHEMBL821
CAS Number
113-00-8
UNII
JU58VJ6Y3B
DrugBank ID
DB00536
VARIDT ID
DR01303
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic cation transporter 3 (SLC22A3) DT6201N S22A3_HUMAN Substrate [4]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Albumin (ALB) OTVMM513 ALBU_HUMAN Protein Interaction/Cellular Processes [5]
Solute carrier family 22 member 3 (SLC22A3) OTQYGVXX S22A3_HUMAN Regulation of Drug Effects [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
4 Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am J Physiol Renal Physiol. 2000 Sep;279(3):F449-58.
5 Spatial relationship between the prodan site, Trp-214, and Cys-34 residues in human serum albumin and loss of structure through incremental unfolding. Biochemistry. 2002 Jun 11;41(23):7443-52. doi: 10.1021/bi025699v.